Sophia Randolph

Sophia Randolph MD PhD is the Chief Medical Officer at ALX Oncology. Previously, Sophia held positions at Pfizer as Executive Director in Oncology and at Merck Inc as Director Clinical Sciences/Oncology. With a background in Biochemistry, Cellular and Molecular Biology, and Internal Medicine/Medical Oncology, Sophia has led the clinical development and strategy for various oncology assets, including pioneering first in class molecules like IBRANCE and vorinostat. Throughout their career, Sophia has demonstrated expertise in trial development, translational medicine, and gene expression profiling strategies in early development clinical trials.